abstract |
The present disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of nucleic acid vaccines comprising polynucleotide sequences encoding one or more structural proteins of SARS-CoV-2 and variants for the treatment, mitigation, amelioration and/or prevention of COVID-19. |